Literature DB >> 21233831

The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.

P Ruminy1, P Etancelin, L Couronné, F Parmentier, V Rainville, S Mareschal, E Bohers, C Burgot, M Cornic, P Bertrand, B Lenormand, J-M Picquenot, F Jardin, H Tilly, C Bastard.   

Abstract

Gene expression profiling has identified two major molecular subtypes of diffuse large B-cell lymphoma (DLBCL) that are histologically indistinguishable but differ in cure rates. Here, we investigated whether the isotype of the B-cell receptor (BCR) expressed by the tumoral cells correlated with the molecular subtype and survival. Gene expression analysis clustered the 53 patients included in this study into three subgroups, 17 germinal center B-cell-like (GCB) cases, 26 activated B-cell-like (ABC) cases and 10 intermediate cases. The molecular subtype was correlated with the isotype, as 15/17 GCB cases expressed a secondary isotype (immunoglobulin (Ig)G or IgA), whereas 24/26 ABC cases expressed a primary isotype (IgM or IgD) (P<0.0001). There was a trend toward a worse outcome for patients with an ABC DLBCL and a shorter overall survival for patients with IgM+ tumor (P=0.21 and 0.014, respectively). Finally, fluorescence in situ hybridization (FISH) analysis revealed a striking asymmetric pattern, as the IGHM gene is conserved only on the productive IGH allele in most IgM+ tumors. Taken together, these data indicate that the isotype of the BCR is a reliable indicator for the GCB and ABC subtypes in DLBCL, and suggest that the conservation of an IgM is required for ABC DLBCL lymphomagenesis to occur.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233831     DOI: 10.1038/leu.2010.302

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

2.  The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.

Authors:  Sylvain Mareschal; Hélène Lanic; Philippe Ruminy; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

Review 3.  Malignant pirates of the immune system.

Authors:  Lixin Rui; Roland Schmitz; Michele Ceribelli; Louis M Staudt
Journal:  Nat Immunol       Date:  2011-09-20       Impact factor: 25.606

Review 4.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

5.  Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.

Authors:  Ryan M Young; Tianyi Wu; Roland Schmitz; Moez Dawood; Wenming Xiao; James D Phelan; Weihong Xu; Laurence Menard; Eric Meffre; Wing-Chung C Chan; Elaine S Jaffe; Randy D Gascoyne; Elías Campo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

6.  VH1-44 gene usage defines a subset of canine B-cell lymphomas associated with better patient survival.

Authors:  Hsiao-Wei Chen; George W Small; Alison Motsinger-Reif; Steven E Suter; Kristy L Richards
Journal:  Vet Immunol Immunopathol       Date:  2013-11-21       Impact factor: 2.046

7.  Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.

Authors:  Joseph D Dekker; Daechan Park; Arthur L Shaffer; Holger Kohlhammer; Wei Deng; Bum-Kyu Lee; Gregory C Ippolito; George Georgiou; Vishwanath R Iyer; Louis M Staudt; Haley O Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

8.  The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs.

Authors:  Leandro Venturutti; Ari M Melnick
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

9.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Alexander Tzankov; Tina Green; Lin Wu; Aarthi Balasubramanyam; Wei-min Liu; Carlo Visco; Yong Li; Roberto N Miranda; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Xiaoying Zhao; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Fan Zhou; Graham W Slack; Randy D Gascoyne; Meifeng Tu; Daina Variakojis; Weina Chen; Ronald S Go; Miguel A Piris; Michael B Møller; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-02-28       Impact factor: 22.113

Review 10.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.